“Better Science, Better Health” hosts a series of international conferences to outline research and innovation in adaptive clinical pathways and patient data usage.
Early Bird: Ever closer Union for cancer patients? How to facilitate access to clinical trials across borders
7 February 2022, 8.30-9.00 CET
Participating in a clinical trial for a new medicine can be the ultimate hope for cancer patients. However, access to clinical trials across borders often remains challenging, even in the European Union: patients are vulnerable and often face high costs, language and cultural challenges, and patients and clinicians must deal with additional legal uncertainties.
The good news is that there is broad consensus amongst European institutions, researchers and their networks, and cancer patients that enabling patients’ access to clinical trials across borders is important. Also, and at just one year old, Europe’s Beating Cancer Plan presents an opportunity to facilitate cross-country clinical trials.
Considering the political will and momentum in Europe, what are practical challenges for patients and researchers to enable more cross-border participation? How can Europe’s Beating Cancer Plan facilitate better legislative, administrative, and regulatory frameworks? What are best practices that can help to find solutions fast enough for patients in need of access to treatments now?
Webinar: Lung Cancer in Europe: New Ideas for Policy Action
15 July, 15.00-16.00 CET
This year more than half a million Europeans will be diagnosed with lung cancer. While many countries have improved the management of lung cancer through better prevention, detection, diagnosis and treatment, the disease continues to claim 1 in 5 cancer deaths across Europe, posing significant challenges to patients and healthcare systems. To identify further opportunities for improvement, The Economist Intelligence Unit made a comparative analysis of lung cancer policies across 27 countries. Over the course of 18 months almost 200 experts provided their insights and advice. During this webinar we will discuss the main findings of this new, landmark study, and discuss in particular the role that governments and policy makers can play in addressing the high burden that lung cancer presents.
Webinar: Head & Neck, the cancer you can see…but its impact is unknown to society
8th July, 2020, 08:30 – 09:00 CET
H&N patients haven´t seen innovation in the disease area for the past 10 years. Those patients face stigma and lack of clear pathways to get early treatment. Are we all doing enough to accelerate the process? How do we make others SEE them?
Webinar: What can Europe learn from Germany’s ‘National Decade Against Cancer’?
17th June 2020, 11.00-12.00 CET
While Europe is working on creating a Cancer Plan, many Member States have national cancer plans and other ambitious initiatives. For example, Germany that is one year into its Decade Against Cancer. German institutions for research and healthcare, the private sector, political institutions and civil society are joining forces for cancer research, cancer prevention and improved therapy of cancer patients. Germany aims to cure or control cancer long-term in 75% of patients by 2030.
What can Europe learn from Germany, and what are the key success factors for a government driven multi-stakeholder action to improve cancer care?
Webinar: Now or later? When is it time to pay for lung cancer screening?
10th June, 2020, 08:30 – 09:00 CET
Lung cancer is responsible for 1 in 5 cancer deaths in Europe. Last year, around half a million Europeans were diagnosed with lung cancer and 400,000 people died of the disease. The survival rates are quite low, but thanks to improvements in diagnosis, surgery, radiotherapy and medicines, they are getting better. The question is, should we screen more aggressively for lung cancer now, or not?.
Webinar: France – A New Method, New Framework, and New Roadmap for Improved Patient Access
20th December 2019, 9am CET
In France, it takes 530 days between market authorisation and patients having access to a new medicine. It’s 374 days in Spain, 111 in the UK, and 106 in Germany. In this webinar we discuss the current access challenges to access to new, innovative oncology treatments in Europe, as well as reforming processes to make reimbursement pathways clearer and more efficient. The objective is to foster timely and appropriate access for those patients with unmet medical needs, and increased clarity and certainty around regulatory access decisions.
Strategic Medicare Contracting Forum – Duane Schulthess discusses the Impact of the IPI on Patients, Outcomes and Innovation
Duane Schulthess discusses the Impact of the IPI on Patients, Outcomes and Innovation
21 November 2019 2.15pm ET
Vital Transformation has conducted two studies examining the impact of the proposed international reference pricing in Medicare Part D on the world-class innovative biotechnology sector in California and the United States.
Webinar: International Reference Pricing – A Failed Strategy for Patients and Innovation?
23rd of October 13.00-14.00 Eastern US
This webinar presents original research by Vital Transformation that will be peer review published in Therapeutic Innovation and Regulatory Science, showing the devastating impact on R&D, Investments, and patients that will be caused by reference pricing in the United States.
Webinar: RWE, CAR-T and Cancer – New Methods for Comparative Effectiveness
With the increasing use of new regulatory tools, like the FDA’s breakthrough therapy designation, there are increasing demands for European health technology assessors (HTAs) to make an accurate assessment of the long-term value and performance of CAR-T therapies from smaller datasets and shorter outcomes. This webinar will highlight our recent publication in the BMJ, sponsored by ZIN, which showcases a novel approach to harnessing RWE and develops a longitudinal data set that can be used for effectiveness measures, even in orphan conditions. As well, we will kickoff our new research project in Diffuse large B-cell lymphoma (DLBCL) and describe how we will leverage our methodology to measure the effectiveness of the various options for treatment, both in emerging CAR-T treatments, as well as existing chemotherapy regimes and bone-marrow transplants.
Tomorrow’s Cures: Impacts of the International Pricing Index
Hosted by GIPC and Vital Transformation Thursday, July 18, 2019 – 4:00 – 5:00 PM Capitol Hill Visitor’s Center (Room 209-08) First St. NE, Washington, DC 20515 We invite you to join us for a discussion on how the International Pricing Index (IPI) penalizes innovation by targeting companies with the most advanced, newest products. Join GIPC and Vital Transformation to discuss the impacts of IPI on patients, outcomes, and innovation.
The International Pricing Index: What will be the Impact on Patients, Outcomes, and Innovation?
Wednesday, June 5, 2019 1:45 PM - 2:45 PM BIO International Convention - Philadelphia, PA Following Vital Transformation's research on investment success factors for biotech companies released at the European Health Forum Gastein, this session will present original research modelling the potential impact both short and long term for patients, payers, and industry for such proposals, and show how the IPI can impact access and innovation broadly. As well, our panellists will place the IPI into the context of other models currently being investigated internationally such as value based payments, managed entry agreements, and adaptive pathways.
Investing in EU Biotech IP – What Works?
4 December 2018 - 2.00-3.00pm CET, 8.00-9.00am ET In this webinar we: • Highlight the results of the research • Expand on the datapackage used • Discuss the gap between EU and US IP productivity in healthcare • Address the need for IP in the global biotech sector
Supporting IP in Europe
Vital Transformation leads a new consortia investigating the relationship between public funding and private investment into new innovative therapies and the supporting system of IP. This project will develop original research investigating the success factors that create successful EU biotech companies and communicate the importance of IP in creating an ecosystem where investors are willing to lose everything 92% of the time, in order to fund the 8% of medical breakthroughs that succeed.